2023

Utidelone recommended by “2023 CSCO Guidelines for Diagnosis and Treatment of Breast Cancer” as Class I

查看大图
2022

UTD1 Phase 3 INDs approved by NMPA for NSCLC and BC neoadjuvant; UTD2 Phase 1 INDs approved by FDA and NMPA

查看大图
2023

Utidelone listed in “China's national reimbursement drug list”

查看大图
2022

Biostar Pharma, Inc. (US subsidiary) incorporated

查看大图
2021

Extraordinary general meeting held and share-holding reform completed

查看大图
2021

Utidelone Injectable NDA approval for the first indication of advanced breast cancer

查看大图
2020

Pre-IPO financing of 890 million RMB

查看大图
2018

Utidelone Injectable NDA submission as priority review

查看大图
2017

Chengdu manufacturing base established for microbial fermentation production and drug product manufacturing

查看大图
2016

Utidelone Injectable Phase 3 reached the primary endpoint

查看大图
2015

Wholly-owned subsidiary incorporated in Chengdu

查看大图
2012

R&D center established covering key biosynthesis platforms

查看大图
2011

Utidelone Injectable Phase 2/3 IND approved

查看大图
2007

Utidelone injectable Phase 1 IND approved

查看大图
2002

Beijing Biostar Pharmaceuticals incorporated in Beijing China

查看大图